Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 15, 2000Journal of Clinical InvestigationOpen Access

Developing aptamers into therapeutics

View Full Paper
Ask AI
Bookmark
Share

Authors

RWRebekah R. WhiteBSBruce A. SullengerCRChristopher P. Rusconi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

White et al. (2000) studied this question.

synapsesocial.com/papers/69daee9b34ded318bb6848cfhttps://doi.org/10.1172/jci11325
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF1991 · 1,072 citations
  2. 2A Clinical Trial of Retroviral-Mediated Transfer of arev-Responsive Element Decoy Gene Into CD34+Cells From the Bone Marrow of Human Immunodeficiency Virus-1–Infected Children1999 · 258 citations
  3. 3Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes1991 · 467 citations
  4. 4Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase1990 · 10,513 citations
  5. 52′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165)1998 · 745 citations